Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.65 |
| ▸ | CTSB | P07858 | 4/20 | 0.64 |
| ▸ | CTSK | P43235 | 7/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823892 | 0.92 | CTSK (0.69) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL7315453 | 0.89 | CAPN1 (0.70) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL7315481 | 0.89 | CAPN1 (0.70) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL8823965 | 0.88 | CTSK (0.58) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL8823907 | 0.88 | CTSK (0.58) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL8823925 | 0.87 | CTSK (0.67) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL8823929 | 0.87 | CTSK (0.67) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL7304278 | 0.87 | CTSL (0.68) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL7304260 | 0.87 | CTSL (0.68) | CTSLCTSBCTSKCAPN1CTSS | |
| SCHEMBL7796791 | 0.86 | CTSL (0.67) | CTSLCTSBCTSKCAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | CTSL 8/4885CTSB 6/4885CTSK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.